Socio-economic aspects of alzheimer's disease

Current Alzheimer Research

Volumn 12, Issue 9, 2015, Pages 903-911

  Marešová, Petra ^a   Mohelská, Hana ^a   Dolejš, Josef ^a   Kuča, Kamil ^a,b  

^a UNIVERSITY OF HRADEC KRALOVE   (Czech Republic)

^b UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

Author keywords

Alzheimer's disease; Costs; Economic aspects; Social aspects

Indexed keywords

ALZHEIMER DISEASE; ARTICLE; BUDGET; ECONOMIC ASPECT; EUROPE; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; META ANALYSIS (TOPIC); PRIORITY JOURNAL; SOCIAL ASPECT; SOCIAL WORKER; COST OF ILLNESS; ECONOMICS; INTERNATIONAL COOPERATION; SOCIOECONOMICS;

ALZHEIMER DISEASE; COST OF ILLNESS; HEALTH CARE COSTS; HUMANS; INTERNATIONALITY; SOCIOECONOMIC FACTORS;

EID: 84946745950     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/156720501209151019111448     Document Type: Article

References (53)

1. WHO: Dementia. The Website of WHO [online]. 2014. Available from http://www.who.int/mediacentre/factsheets/fs362/en/
2. Soukup O, Jun D, Zdarova-Karasova J, Patocka J, Musilek K, Korabecny J, et al. A Resurrection of 7-MEOTA: A Comparison with Tacrin. Curr Alzheimer Res 10(8): 893-906 (2013).
3. Maurer K, Volk S, Gerbaldo H, Auguste D, Alzheimer’s disease. Lancet 349: 1546-1549 (1997).
4. Müller U, Winter P, Graeber MB. A presenilin 1 mutation in the first case of Alzheimer's disease. Lancet Neurol 12(2): 129-130 (2013).
5. Graeber MB, Kösel S, Grasbon-Frodl E, Möller HJ, Mehraein P. Histopathology and APOE genotype of the first Alzheimer disease patient. Neurogenetics 1: 223-28 (1998).
6. Enserink M. First Alzheimer’s diagnosis confirmed. Science 279: 2037 (1998).
7. Rupp C, Beyreuther K, Maurer K, Kins S. A presenilin 1 mutation in the first case of Alzheimer's disease: Revisited. Alzheimers Dementia 10(6): 869-872 (2014).
8. Alzheimer’s Association. Alzheimer’s disease facts and figures. Alzheimers Dement 8(2): 131-68 (2012).
9. Mega MS, Cummings JL, Fiorello T, Gornbein J. The spectrum of behavioral changes in Alzheimer’s disease. Neurology 46(1): 130-5 (1996).
10. Zemek K, Soukup O, Korabecny J, Zemek F, Soukup O, Spilovska K, Musilek K, Jun D, et al. Pharmacotherapy of Alzheimer's disease: current state and future perspectives, Front Drug Des Discov 6: 702-38 (2014).
11. Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer’s disease prevalence. Lancet Neurol 10: 819-28 (2011).
12. Vellas B, Hausner L, Frolich L, Cantet C, Hausner L, Frölich L, et al. Progression of Alzheimer disease in Europe: Data from the European ICTUS study. Curr Alzheimer Res 9(8): 902-912 (2012).
13. Norton S, Matthews FE, Barnes DE, Yaffe K, Brayne C. Potential for primary prevention of Alzheimer’s disease: an analysis of population- based data. Lancet Neurol 13: 788-94 (2014).
14. Pesch B, Kendzia B, Gustavsson P, Jöckel KH, Johnen G, Pohlabeln H, et al. Cigarette smoking and lung cancer - relative risk estimates for the major histological types from a pooled analysis of case-control studies. Int J Cancer 131(5): 1210-9 (2012).
15. Peters SAE, Huxley RR, Woodward M. Diabetes as a risk factor for stroke in women compared with men: a systematic review and meta-analysis of 64 cohorts, including 775 385 individuals and 12 539 strokes. Lancet 383: 1973-80 (2014).
16. Wei EK, Giovannucci E, Wu K, Rosner B, Fuchs CS, Willett WC, et al. Comparison of risk factors for colon and rectal cancer. Intern J Cancer 108(3): 433-42 (2004).
17. MPSV. Preparing for aging. Portal of the Ministry of Labour and Social Affairs [online]. 2008; [cited 2014 June 23]. Available from http://www.mpsv.cz/cs/2856
18. OECD: Health resources. [online]. [cit. 2015-04-15]. Dostupné z: https://data.oecd.org/healthres/health-spending.htm
19. United Nations, Department Of Economic And Social Affairs. Population Division: World Population Prospects: The 2012 Revision, Volume 1: Comprehensive Tables ST/ESA/SER.A/336 [online]. 2013. Available from http://esa.un.org/wpp/Documentation/pdf/WPP2012_Volume-I_Comprehensive-Tables.pdf
20. Association of Independent Unions of the Czech Republic. Materials regular meeting of the 96th Plenary Session of 23 rd February 2012. [online].
21. Ministry of Health of Czech Republic. Health 2020: Framework summary measures [online]. 2013. Available from file:///C:/Users/Maresova/Downloads/WHO_Zdrav%C3%AD_2020_P%C5%99eklad_CZ.pdf
22. WHO. Dementia a public Health priority [online]. 2012. Available from http://apps.who.int/iris/bitstream/10665/75263/1/9789241564458_eng.pdf
23. Castro D, Dillon C, Machnicki G, Allegri R. The economic cost of Alzheimer’s disease: family or public-health burden? Dement Neuropsychol 4: 262-7 (2010).
24. Allegri RF, Butman J, Arizaga RL, Machnicki G, Serrano C, Taragano FE, et al. Economic impact of dementia in developing countries: an evaluation of costs of Alzheimer-type dementia in Argentina. Int Psychogeriatr 19: 705-18 (2007).
25. Wang G, Cheng Q, Zhang S, Bai L, Zeng J, Cui PJ, et al. Economic impact of dementia in developing countries: an evaluation of Alzheimer-type dementia in Shanghai, China. J Alzheimer Dis 15: 109-15 (2008).
26. Lopez-Bastida J, Serrano-Aguilar P, Perestelo-Perez L, Oliva- Moreno J. Social-economic costs and quality of life of Alzheimer disease in the Canary Islands, Spain. Neurology 67: 2186-91 (2006).
27. Zencir M, Kuzu N, Beser NG, Ergin A, Catak B, Sahiner T. Cost of Alzheimer’s disease in a developing country setting, Int J Geriatr Psychiatry 20: 616-22 (2005).
28. Beeri MS, Werner P, Adar Z, Davidson M, Noy S. Economic cost of Alzheimer disease in Israel. Alzheimer Dis Assoc Disord 16: 73- 80 (2002).
29. Boada M, Peña-Casanova J, Bermejo F, Guillén F, Hart WM, Espinosa C, et al. Costs of health care resources of ambulatory-care patients diagnosed with Alzheimer’s disease in Spain. Med Clin (Barc) 113: 690-5 (1999).
30. Ernst RL, Hay JW. The US economic and social costs of Alzheimer’s disease revisited. Am J Public Health 84: 1261-4 (1994).
31. Rice DP, Fox PJ, Max W, Webber PA, Lindeman DA, Hauck WW, et al. The economic burden of Alzheimer’s disease care. Health Aff (Millwood) 12: 164-76 (1993).
32. Ernst RL, Hay JW, Fenn C, Tinklenberg J, Yesavage JA. Cognitive function and the costs of Alzheimer disease. An exploratory study. Arch Neurol 54: 687-93 (1997).
33. Hauber AB, Gnanasakthy A, Snyder EH, Bala MV, Richter A, Mauskopf JA. Potential savings in the cost of caring for Alzheimer’s disease. Treatment with rivastigmine. Pharmacoeconomics 17: 351-160 (2000).
34. Lamb HM, Goa KL. Rivastigmine. A pharmacoeconomic review of its use in Alzheimer’s disease. Pharmacoeconomics 19: 303-18 (2001).
35. Wimo A. Cost effectiveness of cholinesterase inhibitors in the treatment of Alzheimer’s disease: a review with methodological considerations. Drugs Aging 21: 279-95 (2004).
36. Herrmann N, Lanctôt KL, Sambrook R, Lesnikova N, Hébert R, McCracken P, et al. The contribution of neuropsychiatric symptoms to the cost of dementia care. Int J Geriatr Psychiatry 21: 972-6 (2006).
37. Skoldunger A, Johnell K, Winblad B, Wimo A. Mortality and treatment costs have a great impact on the cost- effectiveness of disease modifying treatment in Alzheimer’s disease - a simulation study. Curr Alzheimer Res 10(2): 207-216 (2013).
38. Mesterton J, Wimo A, By A, Langworth S, Winblad B, Jönsson L. Cross sectional observational study on the societal costs of Alzheimer's disease. Curr Alzheimer Res 7(4): 358-67 (2010).
39. Feldman H, Gauthier S, Hecker J, Vellas B, Hux M, Xu Y, et al. Donepezil MSAD Study Investigators Group. Economic evaluation of donepezil in moderate to severe Alzheimer disease. Neurology 63: 644-50 (2004).
40. Sano M, Wilcock G, van Baelen B, Kavanagh S. The effects of galantamine treatment on caregiver time in Alzheimer's disease. Int J Geriatr Psychiatry 18: 942-50 (2003).
41. Solomon A, Akenine U, Andreasen N, Mangialasche F, Wimo A, Jelic V, et al. Practical lessons from amyloid immunotherapy trials in Alzheimer disease. Curr Alzheimer Res 9: 1126-1134 (2012).
42. Phillips C. What is a QALY? Health economics [online]. 2014. Available from http://www.medicine.ox.ac.uk/bandolier/painres/download/whatis/QALY.pdf
43. Buijssen HD. Guide for Family Members and Caregivers. Praha: Portál, p. 136, (2006).
44. Marshall M, Tibbs MA. Social work and people with dementia. Bristol. The Policy Press: 248 (2006).
45. Care Online. Feelings and needs caring for older family members [online]. 2008. Available from http://www.pecujici.cz/priruckyonline.shtml?x=143862
46. JNDP: JPND Research Strategy. The website of JNDP [online]. Available from http://www.neurodegenerationresearch.eu/
47. Alzheimer’s Disease International (ADI): Alzheimer Europe: Annual Report. In: Alzheimer Europe: Dementia [online]. 2011. Available from http://www.alzheimer-europe.org/Alzheimer-Europe/Our-work/Annual-Reports/Annual-Report-2011#fragment-1
48. Kašpárková J. Plans for Alzheimer's - the need, necessity or luxury? Geriatrics and Gerontology [online]. 2013. Available from http://www.cello-ilc.cz/wp-content/uploads/2013/11/plany-Alzheimer.pdf
49. Wimo A, Gustavsson A, McDaid D, Ersek K, Georges J, Gulacsi L, et al. The economic impact of dementia in Europe in 2008: cost estimates from the Eurocode project. Int J Geriatr Psychiatry 26: 825-32 (2010).
50. Wimo A, Johansson L, Jönsson L. The societal costs of dementia and the number of people with dementia in Sweden 2005]. In: Underlagfrån exporter Ed. Socialstyrelsen. Socialstyrelsen, Stockholm; (in Swedish) (2007).
51. Wimo A, von Strauss E, Nordberg G, Sassi F, Johansson L. Time spent on informal and formal care giving for persons with dementia in Sweden. Health Policy 61: 255-68 (2002).
52. Migliaccio-Walle K, Getsios D, Caro JJ, Ishak KJ, O'Brien JA, Papadopoulos G. AHEAD Study Group. Economic evaluation of galantamine in the treatment of mild to moderate Alzheimer's disease in the United States. Clin Ther 25: 1806-25 (2003).
53. Vernon J, Goldberg R, Dash Y, Muralimohan G. Alzheimer’s disease and cost-effectiveness analyses: Ensuring good value for money? ACT–AD (Accelerate Cure/Treatments for Alzheimer’s Disease), May 2007. Available from www.act-ad.org/pdf/Study_Final_051407.pdf